Trial
NCT06694454
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
Phase ISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Non-small Cell Lung Cancer (NSCLC)
Intervention
azacytidine
Why stopped
Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.
Provenance
Dataset: 2026-08-14 • Source: ClinicalTrials.gov API v2 • Last update: 2026-08-14